{
  "asOf": "2026-10-29",
  "review": "Targeted source synthesis; qualified clinical review outstanding",
  "trials": [
    {
      "id": "triumph1-estimands-2026-09",
      "name": "TRIUMPH-1",
      "population": "Adults with obesity without diabetes",
      "design": "Randomized, double-blind, placebo-controlled; 2,339 randomized; 80 weeks",
      "sourceKind": "Peer-reviewed abstract",
      "date": "2026-09-29",
      "endpoint": "Mean body-weight change",
      "estimand": "Treatment-regimen / ITT",
      "values": [
        {
          "label": "Retatrutide 4 mg",
          "value": -17.6
        },
        {
          "label": "Retatrutide 9 mg",
          "value": -23.7
        },
        {
          "label": "Retatrutide 12 mg",
          "value": -25.0
        },
        {
          "label": "Placebo",
          "value": -3.9
        }
      ],
      "unit": "%",
      "sourceUrl": "https://www.nejm.org/doi/full/10.1056/NEJMoa2604169",
      "limit": "Investigational in reviewed sources. Full paper and supplementary safety tables not reviewed."
    },
    {
      "id": "redefine4-head-to-head-2026-02",
      "name": "REDEFINE 4",
      "population": "Obesity with at least one comorbidity",
      "design": "Randomized, open-label, active-controlled; 809 randomized; 84 weeks",
      "sourceKind": "Sponsor topline filed with SEC",
      "date": "2026-02-23",
      "endpoint": "Mean body-weight change",
      "estimand": "Treatment-regimen",
      "values": [
        {
          "label": "CagriSema 2.4/2.4 mg",
          "value": -20.2
        },
        {
          "label": "Tirzepatide 15 mg",
          "value": -23.6
        }
      ],
      "unit": "%",
      "sourceUrl": "https://www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm",
      "limit": "Primary non-inferiority endpoint was not achieved. CagriSema investigational in source; detailed safety rates not supplied in reviewed release."
    },
    {
      "id": "reimagine2-glycaemic-endpoint-2026-06",
      "name": "REIMAGINE 2",
      "population": "Type 2 diabetes on metformin ± SGLT2 inhibitor; BMI ≥25",
      "design": "Randomized, double-blind; 2,713 total; primary arms n=603 and n=605; 68 weeks",
      "sourceKind": "Peer-reviewed abstract",
      "date": "2026-06-07",
      "endpoint": "Mean HbA1c change",
      "estimand": "Efficacy",
      "values": [
        {
          "label": "CagriSema 2.4/2.4 mg",
          "value": -1.91
        },
        {
          "label": "Semaglutide 2.4 mg",
          "value": -1.75
        }
      ],
      "unit": "percentage points",
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/42251859/",
      "limit": "Primary HbA1c estimated difference −0.16 points (95% CI −0.27 to −0.05); full paper not reviewed. CagriSema investigational in sponsor record."
    }
  ]
}